Recent News
2024
Liquid Biopsy Under Development for Measuring Drug Response
May 16, 2024 | The lab of W. Andy Tao, professor of biochemistry at Purdue University, and Tymora Analytical Operations are pioneering a way to assess drug response based on metabolizing proteins found in circulating extracellular vesicles (EVs), which could serve as a surrogate of their expression level in the liver and become therapeutic targets for some cancers.
Tymora joins the team from Purdue and St. Jude Children’s Research Hospital to detect drug response using plasma EVs in a new study
Read the news report on our efforts to develop a new method for monitoring drug response using plasma EVs and our collaborative article published in PNAS Nexus titled “Monitoring drug metabolic pathways through extracellular vesicles in mouse plasma.”
2023
South Carolina-based IMCS, Tymora Analytical Partner to Streamline Exosome Research
Integrated Micro-Chromatography Systems, Inc. (“IMCS”), a leader in automating laboratory workflows, and Tymora Analytical, an authority in exosome purification and proteomics services, have announced a significant enhancement to their ongoing collaboration to advance exosome research.
Read our Diagnostics World news article on our published efforts to identify biomarker signature for Parkinson’s Disease using urine.
Promising ‘Internet Of The Body’ Approach To Diagnosing Parkinson’s Disease.
GenomeWeb article on our recently published manuscript identifying putative non-invasive urine biomarkers for Parkinson’s Disease diagnosis.
Purdue Team Identifies Urinary Protein Markers for Parkinson’s Disease.
We just published an article from our group on quantitative proteomics and phosphoproteomics of urinary EVs for analysis of diagnostic biosignatures in Parkinson’s Disease.
Read our collaborative article published in Nature Communications Medicine titled “Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s Disease.”
We just published an article from our group on quantitative proteomics and phosphoproteomics of urinary EVs for identification of non-invasive biomarkers for renal cell carcinoma.
Read our collaborative article published in Molecular and Cellular Proteomics titled “Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade Differentiation.”
2022
We just published an article from our group on quantitative proteomics and phosphoproteomics of urinary EVs for analysis of diagnostic biosignatures in Parkinson’s Disease.
Read our collaborative article published in medRxiv titled “Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define diagnostic and prognostic biosignatures for Parkinson’s Disease.”
Read our article on the use of urinary EV proteomics for detection of biomarkers for radiation exposure.
Read our collaborative article published in bioRxiv titled “An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure.”
2021
Read our article on the use of phosphoproteomics proteomics analysis carried out by our group on circulating extracellular vesicles in the diabetes spectrum.
Read our collaborative article published in medRxiv titled “Defining the Proteomic and Phosphoproteomic Landscape of Circulating Extracellular
Vesicles in the Diabetes Spectrum.”
We’ve just published our outreach article in the leading science communication publication, Scientia.
We’re excited to announce that Scientia has published our article, “A Non-Invasive, Low-Cost Procedure to Detect Cancer Biomarkers from Biological Fluids.”
Read our article on the use of proteomics analysis carried out by our group on pancreatic cancer cell extracellular vesicles.
Read our collaborative article published in bioRxiv titled “A multi-omics approach identifies pancreatic cancer cell extracellular vesicles as mediators of the unfolded protein response in normal pancreatic epithelial cells.”
Read our article on the use of EV proteomics to examine the toxicity signature pathways in paraquat-exposed human brain microvascular endothelial cells.
Read our article published in Int J Mol Sci titled “Ubiquinone Metabolism and Transcription HIF-1 Targets Pathway Are Toxicity Signature Pathways Present in Extracellular Vesicles of Paraquat-Exposed Human Brain Microvascular Endothelial Cells.”
2020
Plasma-Derived Extracellular Vesicle Phosphoproteomics Through Chemical Affinity Purification
In this article from Dr. Anton Iliuk et al., you’ll learn about the viability of monitoring cancer biomarkers with plasma EV phosphoproteomics and chemical affinity purification.
What are exosomes?
In this video from the New York Medical Diagnostic Center (NYMDC), you’ll learn about exosomes’ generation, their importance to key biological processes, and more.
2019
Tymora Tests for Parkinson’s, Alzheimer’s Featured in Inside Indiana Business
Tymora’s Dr. Anton Iliuk discussed our goal of identifying biomarkers for diseases like Parkinson’s and Alzheimer’s. We strive to do this before symptoms appear, but also non-invasively, with routine urine and blood tests through our EVtrap method. Dr. Iliuk also shares about the funding we’ve been honored to receive that helps us continue our research.
NIH Funds Tymora’s Plasma Exosome Analysis for Alzheimer’s Research
Tymora has accepted a grant from the National Institutes of Health (NIH) to continue studying plasma samples and analyzing them for Alzheimer’s-signaling phosphoproteins with our non-invasive EVtrap approach.
Michael J. Fox Foundation Funds Search for Parkinson’s Urine Biomarkers
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is funding work at Tymora Analytical Operations that screens for protein biomarkers in urine to help detect the neurodegenerative disease earlier.
Diagnosing Early-Stage Parkinson’s Disease via a Urine Test for Extracellular Vesicles
Tymora has accepted a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) that will allow us to study Parkinson’s disease (PD) using our EVtrap approach. This analysis will help us find new urine biomarkers, which can lead to early PD diagnoses and treatment.
2018
Faster liquid biopsies could replace invasive tissue cancer detections
Purdue startup introduces new, less invasive technology for early detection of diseases using liquid biopsies shown to reduce anxiety, enable faster detection and treatment.
GenomeWeb – Tymora Develops Method for Proteomic Analysis of Extracellular Vesicles
Proteomics firm Tymora Analytical Operations has developed a workflow for isolating extracellular vesicles (EVs) and analyzing their protein contents via mass spectrometry.
Anton Iliuk, the CTO of Tymora Analytical, presents at the 2018 Liquid Biopsy Summit (June 20-22, 2018 in San Francisco, CA)
Title of the oral presentation: EV phosphoproteomics as the new source of biomarkers for disease diagnostics.
GenomeWeb – Purdue Team Develops Workflow for Measuring Glycoproteins in Extracellular Vesicles
Purdue University and Tymora Analytical researchers have developed a method for capturing and measuring glycoproteins carried by extracellular vesicles.
2017
GenomeWeb – Tymora developing extracellular vesicle-based phosphoproteomic liquid biopsies
Researchers at Purdue University and Tymora Analytical Operations have developed a method for blood- and urine-based phosphoproteomic analysis that they aim to use to detect and manage various cancers.
Andy Tao, Tymora’s CSO, wins Purdue commercialization award for his work with Tymora Analytical
Purdue start-up advances simple blood, urine tests to detect early-stage cancers
Researchers at Purdue-affiliated company who discovered a way to detect and monitor breast cancer using a simple blood test and bladder cancer using a urine test believe the process can be expanded to diagnose a myriad of early-stage cancers.
USA Today – Could a simple blood test screen for cancer?
Researchers at Purdue University and Tymora Analytical have developed a process to study blood that could open the door to detecting cancer in patients with a simple blood test.
2016
Nanopolymer-modified glycoprotein array can pinpoint cancer
In a recently published study, Purdue University and Tymora Analytical researchers have developed a high-throughput glycoprotein array system and applied it to bladder cancer biomarker discovery from urine.
Recent publication by Tymora Analytical featured on the cover of ChemBioChem
Our paper, “Multiplexed Imaging of Protein Phosphorylation on Membranes Based on Ti(IV) Functionalized Nanopolymers,” was recently featured as the cover of ChemBioChem for their current issue published on May 17, 2016, Volume 17 Issue 10.
2015
Tymora awarded NIH Phase II grant to advance protein phosphorylation tech
NEW YORK (GenomeWeb) – Startup Tymora Analytical Operations this month was awarded a Phase II SBIR grant from the National Institutes of Health to develop multiplexed and reverse-phase array versions of its pImago system for…
Purdue spinout’s approach to building new drug discovery tools
Abnormal protein phosphorylation is viewed as a trigger of most cancers, Alzheimer’s disease and Parkinson’s, Purdue spinout Tymora Analytical Operations is using the analysis of protein phosphorylation as a platform…
2014
Tymora receives $640K NIH Phase I for new biomarker discovery technology
A two-year grant from the National Institutes of Health will fund work by a Purdue Research Park-based company to improve methods to screen blood plasma samples for biomarkers, which are measurable indicators of a disease, to expedite diagnosis and treatment…
Tymora Analytical creates new line of products for cancer research
Cancer researchers in educational and commercial settings have two new tools from a Purdue Research Park-based company to help them with target detection and discovery of novel drugs to fight the disease…
2013
West Lafayette company hopes to improve treatment options for leukemia
West Lafayette company hopes to improve treatment options for leukemia.A company in the Purdue Research Park is collaborating with university researchers and St. Jude Children’s Hospital on improving the treatment of leukemia…
Tymora receives $500,000 NSF Phase II grant for drug-development technology
The National Science Foundation has awarded a Phase II Small Business Innovation Research (SBIR) grant to a life sciences company to develop a technology called pIMAGO that promotes the discovery of new disease targets in laboratory…
2012
Tymora Analytical wins 2012 Indiana Innovation Award for PolyMAC
Tymora wins $300K NIH SBIR grant to improve phosphoproteome analysis
As innovative new cancer therapies become more advanced and targeted, the tools used in researching and developing them should be improved and innovated too. Indiana-based Tymora Analytical Operations LLC is doing that by…
2011
Finding phosphoproteins
Adding or removing a single phosphate group can dramatically change a protein’s activity, and cells make use of this modification to control protein function in response to signals from the environment. Now scientists have developed …